Lipigon Pharmaceuticals AB (LPGO) — Strategic Asset Allocation Index
Lipigon Pharmaceuticals AB (LPGO) has a Strategic Asset Allocation Index of 0.2% as of June 2023. Strategic assets (PP&E of Skr61.00K plus long-term investments of Skr-) total Skr61.00K, measured against net assets of Skr27.59 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check how resilient are Lipigon Pharmaceuticals AB's assets to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Lipigon Pharmaceuticals AB Strategic Asset Allocation Index (2021–2022)
This chart shows how Lipigon Pharmaceuticals AB's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 0.2%, representing strategic assets of Skr61.00K against net assets of Skr27.59 Million SEK. See LPGO financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Lipigon Pharmaceuticals AB (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Lipigon Pharmaceuticals AB from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Lipigon Pharmaceuticals AB market cap and net worth.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.9% | Skr72.00K | Skr72.00K | Skr- | Skr3.87 Million | ▲ +1.4 pp |
| 2021 | 0.4% | Skr96.00K | Skr96.00K | Skr- | Skr22.96 Million | — |